Drug Type Proteolysis-targeting chimeras |
Synonyms- |
Target |
Mechanism CDK9 inhibitors(Cyclin-dependent kinase 9 inhibitors), Proteolysis |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC43H56N10O5 |
InChIKeyYAEBZMQWNHWNAG-BRKUKBBPSA-N |
CAS Registry2411021-01-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | CN | 20 Sep 2021 | |
Triple Negative Breast Cancer | Preclinical | CN | 20 Sep 2021 |